Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid Leukemia

CONCLUSIONS: Patients with CML-CP treated with 1L dasatinib achieved higher rates of, with shorter times to, MMR and DMR versus 1L imatinib. These clinically meaningful improvements were observed across subgroups.PMID:38135632 | DOI:10.1016/j.clml.2023.10.005

Source: Clinical Lymphoma and Myeloma - December 22, 2023 Category: Cancer & Oncology Authors: Andrew J Klink Scott J Keating John Brokars Bruce Feinberg Elias Jabbour Source Type: research